This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): TA-7284, JNJ-28431754, Canagliflozin, Canaglu (Japan), Invocana
Revenue splits are BioMedTracker estimates.
JNJ-28431754 is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. The SGLT2 transporter protein is located only in the kidney, where it normally reabsorbs glucose from urine while waste products are filtered out. Patients with Type 2 diabetes continue to reabsorb glucose from the urine, even though this process contributes to high blood glucose levels, or hyperglycemia.
Canagliflozin was originally developed by Tanabe Seiyaku.
Tanabe Seiyaku and Janssen
In July 2000, Tanabe Seiyaku and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, entered into a collaboration on research and development of SGLT inhibitors. Janssen Pharmaceuticals and its affiliates have marketing rights in North America, South America, Europe, Middle East, Africa, Australia, New Zealand and parts of Asia.
In October 2007, Mitsubishi Tanabe Pharma Corporation was formed by the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation.
Janssen and DepoMed
In August 2010, Depomed reported that they entered into a non-exclusive license agreement with Janssen granting Janssen a license to use certain patents related to our Acuform drug delivery technology in developing fixed dose combinations of canagliflozin and extended release metformin. The Company also granted Janssen a right to reference the New Drug Application...See full deal structure in Biomedtracker
Partners: Mitsubishi Tanabe Pharma Corporation Daiichi Sankyo Co., Ltd. PDL BioPharma, Inc.
Additional information available to subscribers only: